Gamabufotalin, a bufadienolide compound from toad venom, suppresses COX-2 expression through targeting IKKβ/NF-κB signaling pathway in lung cancer cells
- Zhenlong Yu†1,
- Wei Guo†1,
- Xiaochi Ma1Email author,
- Baojing Zhang1,
- Peipei Dong1,
- Lin Huang1,
- Xiuli Wang1,
- Chao Wang1,
- Xiaokui Huo1,
- Wendan Yu1,
- Canhui Yi1,
- Yao Xiao1,
- Wenjing Yang1,
- Yu Qin1,
- Yuhui Yuan1,
- Songshu Meng1,
- Quentin Liu1, 2 and
- Wuguo Deng1, 2Email author
© Yu et al.; licensee BioMed Central Ltd. 2014
Received: 6 May 2014
Accepted: 25 August 2014
Published: 31 August 2014
Gamabufotalin (CS-6), a major bufadienolide of Chansu, has been used for cancer therapy due to its desirable metabolic stability and less adverse effect. However, the underlying mechanism of CS-6 involved in anti-tumor activity remains poorly understood.
The biological functions of gamabufotalin (CS-6) were investigated by migration, colony formation and apoptosis assays in NSCLC cells. The nuclear localization and interaction between transcriptional co-activator p300 and NF-κB p50/p65 and their binding to COX-2 promoter were analyzed after treatment with CS-6. Molecular docking study was used to simulate the interaction of CS-6 with IKKβ. The in vivo anti-tumor efficacy of CS-6 was also analyzed in xenografts nude mice. Western blot was used to detect the protein expression level.
Gamabufotalin (CS-6) strongly suppressed COX-2 expression by inhibiting the phosphorylation of IKKβ via targeting the ATP-binding site, thereby abrogating NF-κB binding and p300 recruitment to COX-2 promoter. In addition, CS-6 induced apoptosis by activating the cytochrome c and caspase-dependent apoptotic pathway. Moreover, CS-6 markedly down-regulated the protein levels of COX-2 and phosphorylated p65 NF-κB in tumor tissues of the xenograft mice, and inhibited tumor weight and size.
Our study provides pharmacological evidence that CS-6 exhibits potential use in the treatment of COX-2-mediated diseases such as lung cancer.
KeywordsGamabufotalin NSCLC COX-2 NF-κB p300 IKKβ
Lung cancer is a leading cause of human death worldwide, and non-small cell lung cancer (NSCLC) comprises approximately 85% of all lung cancers. Although the diagnostic and therapeutic techniques have been improved in recent decades, poor prognosis of NSCLC still leads to a less than 20% five-year survival rate of the patients[1–3]. Therefore, novel therapy strategies are necessary to improve the survival rate of patients with lung cancer.
NF-κB is a family of important transcriptional factors known to regulate a wide range of biological effects, including proliferation, metastasis and apoptosis, via its downstream target genes[4, 5]. NF-κB is sequestered in the cytoplasm in resting cells by the inhibitory IκB proteins. In response to a variety of stimulation, IκB would be phosphorylated by the inhibitor of κB (IKK) kinase complex and further be degraded through ubiquitination–proteasome pathway, thus releasing the active NF-κB dimmers. The free NF-κB then binds to DNA and affects gene expression. Therefore, inhibition of NF-κB activation might be an effective alternative approach to suppress cancer growth.
It has been well documented that COX-2 is a key enzyme involved in cancer development and progression, and plays a central role in the modulation of tumor viability, migration, invasion, and even inflammation[8–10]. COX-2, as the rate-limiting enzymes for the synthesis of prostaglandins from arachidonic acid, is linked to the carcinogenesis of many human cancers, including lung, breast, colon, esophagus, head and neck cancers, and its overexpression is highly related to the poor prognosis of patients[11–16]. Its selective inhibitors could effectively prevent inflammation, proliferation and angiogenesis, and induce apoptosis in human cancer cells. In addition, COX-2 expression is transcriptionally controlled by the binding of multiple transactivators such as NF-κB and coactivators such as p300 and p65 to the corresponding sites of its promoters[17, 18]. Thus, the signals to activate NF-κB have been shown to induce COX-2 expression, implying that the anti-cancer effect of drugs may be concomitant with the downregulation of COX-2 expression.
IKK including IKKα (IKK1) and IKKβ (IKK2), is the convergency point in most signaling pathways activated by many stimuli leading to the inducible phosphorylation and degradation of IκB proteins, thus activated NF-κB. Some studies have clearly demonstrated that although IKKα and IKKβ have a high degree of sequence homology and share similar structural domains, IKKβ has 20–50-fold higher level of kinase activity for IkB than IKKα. Thus, it is essential to identify a small-molecule inhibitor selectively targeting IKKβ, and explore its mechanisms regulating NF-κB activation.
In this study, we investigated the mechanisms of CS-6 for COX-2 suppression in vivo and in vitro, and revealed that CS-6 could target IKKβ to inactive NF-κB signaling pathway and further down-regulate COX-2 expression. Our findings therefore suggested that CS-6 would serve as a potential candidate targeting IKKβ to suppress COX-2 expression for anticancer treatment.
Materials and methods
Chemicals and reagents
Gamabufotalin (CS-6) was isolated from ChanSu by Dr. Xiaochi Ma (Dalian Medical University, Liaoning, China), which was secreted from the postauricular and skin glands of Bufo bufo gargarizans Cantor. The crude materials of ChanSu were purchased from Qingdao, Shandong Province of China. And a voucher specimen had been deposited at School of Pharmacy, Dalian Medical University. A preparative high-speed counter-current chromatography (HSCCC) method for isolation and purification of bufadienolides from ChanSu was developed by using a stepwise elution with two-phase solvent system composed n-hexane-ethyl acetate- methanol–water at the ratios of 4:6:2:4 (v/v), 4:6:2.5:4 (v/v) and 4:6:3.2:4 (v/v). A total of 38 mg of CS-6 was obtained in one-step separation from 1.1 g of the crude extract with purity of 98.7%. Its chemical structure was identified on the basis of 1H-NMR and 13C-NMR technology. All organic solvents for HSCCC separation and preparation of crude extract were the analytical grade (Beijing Chemical Factory, China). For our experiments, the solution of CS-6 (1 μM) in dimethyl sulphoxide (DMSO) was prepared and kept at -20°C, as the stock solution. CS-6 was diluted in culture medium to obtain the desired concentration, which was stable in the dilution with DMSO concentration less than 0.1%. The Phosphate Buffered Saline (PBS), protease inhibitor cocktail and 5-diphenyltetrazolium bromide (MTT) were purchased from Sigma Chemical Co (St. Louis, MO).
Antibodies and other materials
The primary antibodies for COX-2, IKKα, IKKβ, p-IKKα/β, IκB-α, p-IκB-α, cleaved caspase-9, NF-κB p65 and p-p65, β-actin and all the secondary antibodies were obtained from Cell Signaling Technology (Cell Signaling Technology, Inc, USA). The primary antibodies for GAPDH, p300, NF-κB p50, and cytochrome c were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Trypsin, Dulbecco’s Modified Eagle’s Medium (DMEM), RPMI 1640 and fetal bovine serum (FBS) were obtained from HyClone Laboratories (HyClone Laboratories Inc.). All other chemicals were purchased from Sigma Chemical Co. (St. Louis, MO) unless otherwise specified.
Human NSCLC H1299, A549, H322 and H460 cell lines and human embryonic lung fibroblasts HLF cell line were obtained from ATCC (Manassas, VA). Cells were maintained in either DMEM medium or RPMI 1640 medium supplemented with 10% fetal bovine serum. All cell cultures were maintained at 37°C in a humidified atmosphere containing 5% CO2.
Cell viability assay
Cell viability was determined by a MTT assay (Roche Diagnosis, Indianapolis, IN). Briefly, lung cancer cell lines were seeded at 6 × 103 cells/well in 96-well plates. Cells were allowed to adhere for overnight, and then the cells were changed to fresh medium containing various concentrations of CS-6 (0, 10, 50 and 100 nM) dissolved in DMSO (final concentration, 0.1%). After 48 h incubation, the growth of cells was measured. The effect on cell viability was assessed as the percent cell viability compared with untreated control group, which were arbitrarily assigned 100% viability. The CS-6 concentration required to cause 50% cell growth inhibition (IC50) was determined by interpolation from dose–response curves. All experiments were performed in triplicate.
In vitro migration assay
Scratch assay (wound healing assay) was performed to detect cell migration. The cells were grown to full confluence in six-well plates and wounded with a sterile 100 ul pipette tip after 6 h of serum starvation and then washed with starvation medium to remove detached cells from the plates. Cells were treated with indicated doses of CS-6 in full medium and kept in a CO2 incubator. After 48 h, medium was replaced with phosphate buffered saline (PBS) buffer, the wound gap was observed, and cells were photographed using a Leica DM 14000B microscope fitted with digital camera.
Colony formation assay
To analyze the cell sensitivity to CS-6, we used a colony formation assay in vitro. Briefly, A549 cells (0.8 × 103 per well) were seeded in six-well plate containing 2 ml growth medium with 10% FBS and cultured for 24 h. Then, removed the medium, and cells were exposed to various concentrations of CS-6 (0, 10, 50 and 100 nM). After 24 h, cells were washed with PBS and supplemented fresh medium containing 10% FBS. The cultures were maintained in a 37°C, 5% CO2 incubator for 14 days, allowing viable cells to grow into macroscopic colonies. Removed the medium, and the colonies were counted after staining with 0.1% crystal violet.
Apoptosis was measured by fluorescence-activated cell sorter (FACS) using the Annexin V- FITC Apoptosis Detection Kit (Nanjing KeyGEN Biotech. CO., LTD.). In brief, cells plated in 6-well plates were treated with CS-6. After treatment of 12 h, cells were collected and washed once with cold PBS, and subsequently stained simultaneously with FITC-labeled annexin V and PI. Stained cells were analyzed using FACS Accuri C6 (Genetimes Technology Inc.).
Western blot analysis
Cell lysate proteins were separated by electrophoresis on a 7.5-12% sodium dodecyl sulfate-polyacrylamide minigels (SDS-PAGE) and then electrophoretically transferred to a PVDF membrane. Western blots were probed with the specific antibodies. The protein bands were detected by enhanced chemiluminescence. Similar experiments were performed at least three times. The total protein concentration was determined using a BCA protein assay kit.
Immunofluorescence staining was done in cells cultured in chamber slides. After CS-6 treatment, the cells were washed in phosphate-buffered saline (PBS) and fixed for 10 min at room temperature (RT) with 4% paraformaldehyde. The samples were permeabilized with 0.2% TritonX-100 for 5 min. And then blocked with 10% bovine serum albumin (BSA) in PBS for 30 min. Antibodies against Cytochrome c, p65, p50, and p300 in the 1% blocking solution were added to the sample and incubated for overnight at 4°C. Following three 10-min washes with PBS, fluorescein isothiocyanate- and rhodamine-conjugated secondary antibodies were added in 1% blocking solutions and incubated for 1 hr. Subsequently, the stained samples were mounted with 4′, 6-diamidino-2-phenylindole (DAPI)-containing Vectashield solution (Vector Laboratories Inc.) to counterstain cell nuclei. After five additional 5-min washes, samples were examined with a Leica DM 14000B confocal microscope.
DNA-protein binding by streptavidin-agarose pulldown assay
Binding of p300 or p65, p50 NF-κB to COX-2 core promoter probes were determined by a streptavidin-agarose pulldown assay. A biotin-labeled double-stranded probe corresponding to COX-2 promoter sequence was synthesized. The binding assay was performed by mixing 400 μg of nuclear extract proteins, 4 μg of the biotinylated DNA probe and 40 μl of 4% streptavidin-conjugated agarose beads at room temperature for 5 h in a rotating shaker. Beads were pelleted by centrifugation to pull down the DNA-protein complex. DNA-bound p300 or p65, p50 NF-κB protein was dissociated by boiled in 30 μl of 2X Laemmli sample buffer and analyzed by Western blotting.
Reverse transcription-polymerase chain reaction (RT-PCR)
Z138 cells were treated with different concentrations of CS-6 (0, 10, 50, and 100 nM) for 48 h and then harvested. Total cellular RNA was extracted using the RNAiso Plus reagent, according to the manufacturer’s protocol (TaKaRa Biotechnology, Dalian, China). Total RNA (1.5 ug) was reverse-transcribed using the PrimeScriptTM RT-PCR Kit (TaKaRa). PCR analysis was performed on aliquots of the cDNA preparations to detect gene expression. PCR was programmed as follows: 5 min at 95°C followed by 35 cycles (30 for GAPDH), 30 s at 94°C, 30 s at 60°C, and 1 min at 72°C. RT-PCR products were analyzed via 1.0% agarose gel electrophoresis and stained with Gold View for visualization using ultraviolet light.
Quantitative real-time reverse transcription polymerase chain reaction (RT-qPCR)
Total RNA was extracted from A549 cells after treatment with CS-6 for 48 h, using TRIzol reagent according to the kit protocol (TaKaRa Bio, Dalian, China). cDNA was reverse-transcribed using the PrimeScript RT Reagent Kit (TaKaRa Bio, Dalian, China) according to the manufacturer’s instructions. The Q-PCR reaction was performed following the kit protocol (TaKaRa Bio, Dalian, China), and amplification was performed using the Mx3005P Real-Time PCR System (Agilent, CA, USA). The relative mRNA expression of each gene was normalized to GAPDH RNA levels and analyzed using the 2-ΔΔCT method. The primers were synthesized by invitrogen (Shanghai, China). The primers for COX-2 were: 5′-TCACAGGCTTCCATTGAC CAG-3 and 5′-CCGAGGCTTTTCTACCAGA-3′; the primers for β-actin were: 5′-GGCACCCAGCACAATGAA-3′ and 5′-TAGAAGCATTTGCGGTGG -3′.
The chromatin immunoprecipitation (ChIP) assay was performed as previously described. In brief, about 80% confluent cells were used for the experiments after exposed to CS-6 for 48 h. 1% paraformaldehyde was added to the cell-culture medium to cross-link, and after incubation for 10 min at 37°C with gently shaking, the cells were washed twice in cold phosphate-buffered saline, scraped, and lysed in lysis buffer (1% SDS, 10 mM Tris–HCl, pH 8.0, with 1 mM phenylmethylsulfonyl fluoride, pepstatin A, and aprotinin) for 10 min at 4°C. The lysates were sonicated five times for 15 s each time, and the debris was removed by centrifugation. A 20-μl aliquot was removed to serve as an input sample. The remaining of the lysate were diluted 10-fold with a dilution buffer (0.01% SDS, 1% Triton X-100, 1 mM EDTA, 10 mM Tris–HCl, pH 8.0, and 150 mM NaCl) followed by incubation with antibodies against specific transactivators or a nonimmune rabbit IgG control overnight at 4°C. Immunoprecipitated complexes were collected using protein A/G plus agarose beads. The precipitates were extensively washed and incubated in an elution buffer (1% SDS and 0.1MNaHCO3) at room temperature for 20 min. Cross-linking of protein–DNA complexes was reversed at 65°C for 5 h, followed by treatment with 100 ug/mL proteinase K for 2 h at 37°C. DNA was extracted three times with phenol/chloroform and precipitated with ethanol. The pellets were resuspended in TE buffer and subjected to PCR amplification using specific COX-2 promoter primers (Forward primer: ACGTGACTTCCTCGACCCTC, and Reverse primer: AAGACTGAAAA CCAAGCCCA). The resulting product of 478 bp for COX-2 in length was separated by 1.0% agarose gel electrophoresis.
The molecular docking studies were performed to explore the potential binding mode between CS-6 and IKKβ protein complex. CS-6 was optimized using the semi-empirical PM3 method with the Polak-Ribie’re conjugate gradient algorithm with an RMS gradient of 0.01 kcal mol-1 Å-1 as convergence criterion. The optimized structure of CS-6 was docked into the active site of IKKβ with ligand K-252A (PDB Code: 4KIK). The crystallographic ligand was extracted from the active site, and the residues within a 6.5 A° radius around IKKβ molecule were defined as the active pocket. The Surflex-Dock program was used for the docking calculations with default parameters. MOLCAD surfaces were generated for visualizing the binding mode of the docked protein–ligand complexes.
All animals were maintained, and animal experiments were done in SPF Laboratory Animal Center at Dalian medical university. The animals used in this study were female nu/nu mice (4–6 weeks old). To evaluate the therapeutic efficacy of CS-6 in a human A549 orthotopic lung cancer mouse model, A549 cells (2 × 106 in 100 μL PBS) were injected subcutaneously near the axillary fossa of the nude mice using a 27-gauge needle. The tumor cell–inoculated mice were randomly divided into three treatment groups that each contained five mice. Two weeks later, when the tumor diameters reached 3 mm × 4 mm, group A was treated with PBS; group B with 100 ug/20 g CS-6; group C with 100 ug/20 g CS-6 by intraperitoneal injection every day. Tumors were measured with a caliper every 2 days, and the tumor volume was calculated using the formula V = 1/2 (width2 × length). Body weights were also recorded. On day 30 after tumor cell inoculation, all experimental mice were terminated with ether anesthesia and the total weight of the tumors in each mouse was measured. To determine COX-2 or p65 NF-κB expression, the tumor tissues were harvested and freshly fixed with 10% neutral formalin and desiccated and embedded in paraffin. 4 μm sections were stained with hematoxylin and eosin, COX-2 antibody (1:80) and p-p65 NF-κB (1:150) antibody, and examined under a light microscope. The images were examined under a Leica DM 4000B fluorescence microscope equipped with a digital camera.
All animal maintenance and procedures were carried out in strict accordance with the recommendations established by the Animal Care and Ethics Committee of Dalian Medical University as well as the guidelines by the U.S. National Institutes of Health Guide for the Care and Use of Laboratory Animals. The protocol was approved by the Animal Care and Ethics Committee of Dalian Medical University. In animal study, all efforts were made to minimize suffering of mice. All mice were humanely sacrificed by ether anesthesia inhalation before death.
All experiments were repeated three times. Data are represented as mean ± standard deviation (SD). Analysis of variance and Student’s t-test were used to compare the values of the test and control samples in vitro and in vivo. P < 0.05 was considered to be a statistically significant difference. SPSS 17.0 software was used for all statistical analysis.
CS-6 inhibited NSCLC cell proliferation and changed cell morphology
Cell viability plays an essential role in carcinogenesis, and its inhibition is crucial to treat cancer. Firstly, we quantitatively examined the effect of CS-6 (Figure 1A) on cell morphology and cell proliferation of several human lung cancer cell lines by MTT assay. As shown in Figure 1B, CS-6 markedly reduced cell-to-cell contact and had lower spreading with fewer formation of filopodia compared with the DMSO vehicle control groups. Interestingly, treatment with CS-6 resulted in the dose-dependent growth inhibition of NSCLC cells, but has no cytotoxicity in human normal lung cell line (HLF cells) at the same dose (Figure 1C).
CS-6 suppressed colony formation and migration of NSCLC cells
CS-6 induced apoptosis via modulating cytochrome c and caspase signaling
Apoptosis is a cell suicide mechanism that enables organisms to control cell numbers and eliminate malignant cells that threaten survival. Induction of apoptosis in target cells is a key mechanism for anti-cancer therapy. We next determined whether the enhancement of cell growth inhibition induced by CS-6 is associated with the increase of apoptosis in lung cancer cells. We conducted a time-course study for the effect of CS-6 on apoptosis using two effective concentrations. The results showed that CS-6 treatment resulted in a significant dose-dependent induction of apoptosis in A549 cells. We also found that the induction of apoptotic cells by CS-6 had significant difference between 12 h and 24 h or 48 h, but had no difference between 24 h and 48 h.
CS-6 suppressed COX-2 expression in NSCLC cells
COX-2 expression has been demonstrated to induce cell proliferation, migration, and angiogenesis in cancer cells. To determine whether CS-6 influenced COX-2 signaling in lung cancer cells, expression level of COX-2 gene and protein in the CS-6 treated cancer cells was detected by RT-PCR, RT-qPCR and Western blot, respectively. As shown in Figures 4A,B and C, the CS-6 effectively inhibited COX-2 expression at both protein and mRNA levels in A549 cells in a dose-dependent manner. To determine whether CS-6 also inhibited COX-2 expression in other NSCLC cells, we treated H322 and H460 cells with CS-6 at different doses, and found that CS-6 also considerably suppressed COX-2 protein expression in both H322 and H460 cells.
To further confirm the role of CS-6 in regulating the COX-2 signaling in lung cancer cells, A549 cells were treated with CS-6 (50 nM) after COX-2-selective inhibitor celecoxib (CB, 25 uM and 50 uM) pretreatment at 8 h. After continuous incubation of 48 h, the cell proliferation was analyzed by a MTT assay. As shown in Figure 4E, treatment of cells with different dosage of CB alone has different inhibitory effect on cell viability, however, the combined treatment with CS-6 (50 nM) and CB did not markedly affect the cell viability compared with CS-6 treatment alone. These results suggested that CS-6 might also partially inhibit the activation of the COX-2 signaling, thereby affecting cell viability.
CS-6 inhibited NF-κB and p300 translocation and binging to COX-2 promoter
Previous reports suggested that NF-κB is an important transcription factor that regulates the expression of COX-2 and inflammatory cytokines[4, 29], the region of COX-2 gene promoter contains a binding sequence for NF-κB[30, 31], and transcriptional coactivator p300 can bind to promoter-bound transactivators such as NF-κB to regulate COX-2 gene expression in cancer cells. We next performed immunofluorescence assay to confirm the nuclear localization and interaction between p300 and NF-κB in A549 cells. Constitutive translocation of NF-κB p50/p65 and coactivator p300 to the cell nucleus and the colocalization of p50 with p65 and p300 were detected in A549 cells. Treatment with CS-6 markedly inhibited translocation of the NF-κB p65/p50 proteins from cell cytoplasm to nucleus and caused p300 into the cytoplasm by comparison with the DMSO control (Figure 5A). The results indicate that the inhibition of A549 cell proliferation by CS-6 might be mediated by inhibiting NF-κB and p300 translocation form cell nuclei to cytoplasm to further inhibit COX-2 expression.
CS-6 inhibited IKKβ activity by targeting the ATP binding site
Since IκB kinase (IKK) complex is required for NF-κB activation, and its one member, IKKβ, is a major upstream kinase of IκB-α canonical NF-κB signaling pathway, we then investigated whether CS-6 exert some influence on IKK activity with an aim to better understand the related molecular events.. As shown in Figure 6A, pretreatment with CS-6 not only significantly suppressed the phosphorylation of p-IKKβ in A549 cells without affecting their overall IKKβ expression, but also decreased the expression level of p-IκB-α. Thereafter, we hypothesized that CS-6 might bind to IKKβ and subsequently inhibited its kinase activity. To test this hypothesis, computer molecular modeling assay was conducted to simulate the interactions between CS-6 and IKKβ. Molecular docking studies predicted that CS-6 could bind to ATP binding site of IKKβ. Specifically, as shown in Figure 6B (Left), CS-6 formed three hydrogen bonds with the ATP binding pocket of the IKKβ kinase domain. The CO motif at the lactonic ring of CS-6 forms a hydrogen bond with the backbone NH of Cys99. The OH group at the C-30 position forms an additional hydrogen bond to the carbonyl oxygen of Glu149. Moreover, the OH group at the C-14 position accepts a hydrogen bond with the CO of Asn28. The result of MOLCAD surface modeling indicated that the lacton ring of CS-6 extends into the deep hydrophobic cavity of the ATP-binding pocket (Figure 6B, Right). As expected, both p-p65 expression level in cytoplasmic and p65, p50 expression in nuclear decreased significantly after CS-6 treatment (Figure 6C). All of these results supported that IKKβ was a target of CS-6 in the NF-κB signaling pathway to suppressed COX-2 expression.
CS-6 inhibited the growth of lung cancer xenografts in nude mice
Toad Venom, a traditional Chinese medicine (TCM), is an anti-inflammatory drug used in small doses for the treatment of various types of inflammation in China[32, 33]. Bufadienolides, such as bufalin and cinobufagin as its major active ingredients, exhibited the significant antitumor activities, including inhibition of cell proliferation, induction of apoptosis, inhibition of cancer angiogenesis, and regulation of the immune response. Meantime, Toad Venom extracts or bufadienolides also exhibited the significant anti-inflammatory action by inhibiting the proliferations of human T-lymphocytes. However, there is little known about the biological effects of other toad venom ingredients in vivo and in vitro. Gamabufotalin (CS-6) is a major bufadienolide with better drug ability, but only few researches have studied on its biological activities.
In the present study, we found that gamabufotalin (CS-6) could effectively inhibit NSCLC cells growth and enhance apoptosis induction dose-dependently with IC50 of only 50 nM, while CS-6 nearly had no adverse effect on human normal lung tissue cells at the dosage of 10 μM. Furthermore, we showed that the effects of CS-6 on lung cancer cells growth and apoptosis were mediated through inhibiting NF-κB/COX-2 signaling pathway and activating the cytochrome c/caspase-dependent apoptotic pathway. CS-6 inhibited COX-2 expression through suppressing the phosphorylation of IKKβ by targeting the ATP-binding site, thereby inhibiting translocation of the NF-κB p65/p50 proteins from cell cytoplasm to nucleus and abrogating NF-κB binding and p300 recruitment on COX-2 promoter. Here, to the best of our knowledge, it might be the first time to report the treatment of CS-6 on COX-2 expression and to demonstrate the underlying mechanisms both in vitro and in vivo.
In our study, considering that A549 cell line overexpresses COX-2 and has a higher ability to form xenograft in nude mice, we performed almost in vitro experiments in A549 cells to study the molecular mechanism of CS-6 suppressing COX-2 expression.
One of the pivotal roles in the inflammatory processes is cyclooxygenase-2 (COX-2), an inducible enzyme, which can be rapidly induced by inflammatory mediators, cytokines, growth factors and tumour promoters[34–36]. Previous studies have shown that COX-2 overexpression has a significantly central role to in cancer development by promoting cell proliferation, decreasing apoptosis rate, and increasing invasive and metastatic potential of the primary tumor[37–39]. To clarify the mechamism of CS-6 from Chansu used as an anti-cancer agent, we investigated whether COX-2 plays an important role in CS-6 bioactive function, and found CS-6 could inhibit COX-2 expression, along with inhibiting NSCLC viability, migration and colony formation.
The transcription factor NF-κB has been shown to be involved in COX-2 expression in various cell types. Transcriptional coactivator p300 could increase the transcriptional activity of the NF-κB complex through modification of chromatin structure and the direct acetylation of p65 and p50. These evidences suggested that the activation of NF-κB complex p300 played an important role in bridging the multiple DNA-bound transactivators with transcription factors to initiate COX-2 transcription. In our study, we confirmed the nuclear localization and interaction of NF-κB and p300 in lung cancer cells, and found that CS-6 inhibited NF-κB translocation from cytosol to nuclear and its binding to COX-2 promoter, abrogating COX-2 transcriptional activation, thereby reduce COX-2 expression. In our study, we found that CS-6 inhibited COX-2 expression and induced apoptosis; however, no direct correlation between them was observed.
NF-κB is kept in an inactive state in the cytoplasm by interacting with members of the IκB family of proteins which mask the nuclear translocation signal of NF-κB. Upon stimulation, IκB proteins become phosphorylated at Ser32 and Ser36 residues by the inhibitor of κB (IKK) kinase complex, ensuing degradation. Therefore, IKK is essential to NF-κB activation. Next, we studied whether CS-6 could affect IKK activity. Our present study strongly indicated that CS-6 could inhibit serine phosphorylation of IKKβ in a dose-dependent manner. Moreover, computational docking implied that CS-6 occupied the deep hydrophobic pocket in the ATP-binding site of IKKβ. In this modeling analysis, CS-6 located well in the ATP binding site and interacted with the hinge region backbone residue Cys99, and also makes hydrogen bond interaction with Glu149, same as K-252A, which may be another reason for higher inhibition activity[43, 44]. Our results suggested that CS-6 might block the nucleotide recognition domain binding with ATP, as a reversible inhibitor. This is just consistent with our experimental results. Hydrophobic interactions should be emphasized because the ATP binding pocket is consisted of a narrow and hydrophobic region. These data mentioned above suggested that CS-6 may attenuate the transcriptional activity of NF-κB, at least in part, by abrogating the activity of IKKβ. IKKα and IKKβ are the two catalytic subunits of IKK, and have a high degree of sequence homology and share similar structural domains. However, previous studies have clearly demonstrated that IKKβ subunits of IKK complex are required for NF-κB activation by all known pro-inflammatory stimuli including lipopolysaccharide (LPS), TNFα and IL-1β[45, 46]. Thus, we mainly focus on the effect of CS-6 on IKKβ in the present study.
In conclusion, we found that CS-6 suppresses COX-2 expression in lung cancer, both in vivo and in vitro. Mechanistic investigation reveals that CS-6 may target IKKβ signaling cascades. These findings provide strong evidences for potential of CS-6 to be a novel anti-cancer agent in NSCLC treatment.
This work was supported by the funds from the National Natural Science Foundation of China (81274047,81473334, 81301721, 81272195, 81071687); the State “973 Program” of China (2014CB542005); the Education Department of Liaoning Province, China (the “Program for Pan-Deng scholars”; the "Program for Liaoning Excellent Talents in University (LR2014025)", and Dalian Outstanding Youth Science and Technology Talent for funding towards this research.
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61: 69-90.View ArticlePubMedGoogle Scholar
- Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin. 2010, 60: 277-300.View ArticlePubMedGoogle Scholar
- Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA: Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008, 83: 584-594.PubMed CentralView ArticlePubMedGoogle Scholar
- Arsura M, Cavin LG: Nuclear factor-kappaB and liver carcinogenesis. Cancer Lett. 2005, 229: 157-169.View ArticlePubMedGoogle Scholar
- Jost PJ, Ruland J: Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood. 2007, 109: 2700-2707.PubMedGoogle Scholar
- Brown K, Gerstberger S, Carlson L, Franzoso G, Siebenlist U: Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation. Science. 1995, 267: 1485-1488.View ArticlePubMedGoogle Scholar
- Ling J, Kumar R: Crosstalk between NFkB and glucocorticoid signaling: a potential target of breast cancer therapy. Cancer Lett. 2012, 322: 119-126.View ArticlePubMedGoogle Scholar
- Kajita S, Ruebel KH, Casey MB, Nakamura N, Lloyd RV: Role of COX-2, thromboxane A2 synthase, and prostaglandin I2 synthase in papillary thyroid carcinoma growth. Mod Pathol. 2005, 18: 221-227.View ArticlePubMedGoogle Scholar
- Wang D, Dubois RN: The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene. 2010, 29: 781-788.PubMed CentralView ArticlePubMedGoogle Scholar
- Guillem-Llobat P, Dovizio M, Alberti S, Bruno A, Patrignani P: Platelets, cyclooxygenases, and colon cancer. Semin Onco. 2014, 41: 385-396.View ArticleGoogle Scholar
- Grimminger PP, Stohlmacher J, Vallbohmer D, Schneider PM, Holscher AH, Metzger R, Danenberg PV, Brabender J: Prognostic significance and clinicopathological associations of COX-2 SNP in patients with nonsmall cell lung cancer. J Oncol. 2009, 2009: 139590-PubMed CentralView ArticlePubMedGoogle Scholar
- Marks F, Muller-Decker K, Furstenberger G: A causal relationship between unscheduled eicosanoid signaling and tumor development: cancer chemoprevention by inhibitors of arachidonic acid metabolism. Toxicology. 2000, 153: 11-26.View ArticlePubMedGoogle Scholar
- Federico A, Morgillo F, Tuccillo C, Ciardiello F, Loguercio C: Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer. 2007, 121: 2381-2386.View ArticlePubMedGoogle Scholar
- Meyer AM, Dwyer-Nield LD, Hurteau GJ, Keith RL, O’Leary E, You M, Bonventre JV, Nemenoff RA, Malkinson AM: Decreased lung tumorigenesis in mice genetically deficient in cytosolic phospholipase A2. Carcinogenesis. 2004, 25: 1517-1524.View ArticlePubMedGoogle Scholar
- Nakanishi M, Rosenberg DW: Roles of cPLA2alpha and arachidonic acid in cancer. Biochim Biophys Acta. 2006, 1761: 1335-1343.PubMed CentralView ArticlePubMedGoogle Scholar
- Edwards J, Mukherjee R, Munro AF, Wells AC, Almushatat A, Bartlett JM: HER2 and COX2 expression in human prostate cancer. Eur J Cancer. 2004, 40: 50-55.View ArticlePubMedGoogle Scholar
- Shi D, Xiao X, Wang J, Liu L, Chen W, Fu L, Xie F, Huang W, Deng W: Melatonin suppresses proinflammatory mediators in lipopolysaccharide-stimulated CRL1999 cells via targeting MAPK, NF-kappaB, c/EBPbeta, and p300 signaling. J Pineal Res. 2012, 53: 154-165.View ArticlePubMedGoogle Scholar
- Deng WG, Zhu Y, Wu KK: Role of p300 and PCAF in regulating cyclooxygenase-2 promoter activation by inflammatory mediators. Blood. 2004, 103: 2135-2142.View ArticlePubMedGoogle Scholar
- Li J, Peet GW, Pullen SS, Schembri-King J, Warren TC, Marcu KB, Kehry MR, Barton R, Jakes S: Recombinant IkappaB kinases alpha and beta are direct kinases of Ikappa Balpha. J Biol Chem. 1998, 273: 30736-30741.View ArticlePubMedGoogle Scholar
- May BH, Lu C, Bennett L, Hugel HM, Xue CC: Evaluating the traditional Chinese literature for herbal formulae and individual herbs used for age-related dementia and memory impairment. Biogerontology. 2012, 13: 299-312.View ArticlePubMedGoogle Scholar
- Xingping L, Zongde Z, Yanfang Z, Liren C, Yongmin L: Microemulsion electrokinetic chromatographic determination of bufadienolides in toad venom and in traditional Chinese medicine. Anal Bioanal Chem. 2006, 384: 1254-1258.View ArticlePubMedGoogle Scholar
- Chen KK, Kovarikova A: Pharmacology and toxicology of toad venom. J Pharm Sci. 1967, 56: 1535-1541.View ArticlePubMedGoogle Scholar
- The State Pharmacopoeia Commission of People’s Republic of China : Pharmacopoeia of the People’s Republic of China. 2010, 360-Beijing: China Chemical Industry PressGoogle Scholar
- Moreno YBL, Katz A, Miklos W, Cimmino A, Tal DM, Ainbinder E, Zehl M, Urban E, Evidente A, Kopp B, Berger W, Feron O, Karlish S, Kiss R: Hellebrin and its aglycone form hellebrigenin display similar in vitro growth inhibitory effects in cancer cells and binding profiles to the alpha subunits of the Na+/K + -ATPase. Mol Cancer. 2013, 12: 33-View ArticleGoogle Scholar
- Mori H, Sugie S, Yoshimi N, Hara A, Tanaka T: Control of cell proliferation in cancer prevention. Mutat Res. 1999, 428: 291-298.View ArticlePubMedGoogle Scholar
- Hajra KM, Liu JR: Apoptosome dysfunction in human cancer. Apoptosis. 2004, 9: 691-704.View ArticlePubMedGoogle Scholar
- Kasibhatla S, Tseng B: Why target apoptosis in cancer treatment?. Mol Cancer Ther. 2003, 2: 573-580.PubMedGoogle Scholar
- Zhou F, Wu S, Wu B, Chen WR, Xing D: Mitochondria-targeting single-walled carbon nanotubes for cancer photothermal therapy. Small. 2011, 7: 2727-2735.View ArticlePubMedGoogle Scholar
- Chun KS, Surh YJ: Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochem Pharmacol. 2004, 68: 1089-1100.View ArticlePubMedGoogle Scholar
- Kim Y, Fischer SM: Transcriptional regulation of cyclooxygenase-2 in mouse skin carcinoma cells. Regulatory role of CCAAT/enhancer-binding proteins in the differential expression of cyclooxygenase-2 in normal and neoplastic tissues. J Biol Chem. 1998, 273: 27686-27694.View ArticlePubMedGoogle Scholar
- Guo LY, Hung TM, Bae KH, Shin EM, Zhou HY, Hong YN, Kang SS, Kim HP, Kim YS: Anti-inflammatory effects of schisandrin isolated from the fruit of schisandra chinensis baill. Eur J Pharmacol. 2008, 591: 293-299.View ArticlePubMedGoogle Scholar
- Wang YL, He SX, Luo JY: Progress in research on antitumor activity of saikosaponin and its mechanism. Zhong Xi Yi Jie He Xue Bao. 2006, 4: 98-100.View ArticlePubMedGoogle Scholar
- Terness P, Navolan D, Dufter C, Kopp B, Opelz G: The T-cell suppressive effect of bufadienolides: structural requirements for their immunoregulatory activity. Int Immunopharmacol. 2001, 1: 119-134.View ArticlePubMedGoogle Scholar
- Smith WL, DeWitt DL, Garavito RM: Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem. 2000, 69: 145-182.View ArticlePubMedGoogle Scholar
- Boolbol SK, Dannenberg AJ, Chadburn A, Martucci C, Guo XJ, Ramonetti JT, Abreu-Goris M, Newmark HL, Lipkin ML, DeCosse JJ, Bertagnolli MM: Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res. 1996, 56: 2556-2560.PubMedGoogle Scholar
- Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE, Schror K: Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res. 1999, 59: 198-204.PubMedGoogle Scholar
- Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998, 93: 705-716.View ArticlePubMedGoogle Scholar
- Cianchi F, Cortesini C, Fantappie O, Messerini L, Sardi I, Lasagna N, Perna F, Fabbroni V, Di Felice A, Perigli G, Mazzanti R, Masini E: Cyclooxygenase-2 activation mediates the proangiogenic effect of nitric oxide in colorectal cancer. Clin Cancer Res. 2004, 10: 2694-2704.View ArticlePubMedGoogle Scholar
- Jones DJ, Lamb JH, Verschoyle RD, Howells LM, Butterworth M, Lim CK, Ferry D, Farmer PB, Gescher AJ: Characterisation of metabolites of the putative cancer chemopreventive agent quercetin and their effect on cyclo-oxygenase activity. Br J Cancer. 2004, 91: 1213-1219.PubMed CentralView ArticlePubMedGoogle Scholar
- Yang CM, Chien CS, Hsiao LD, Luo SF, Wang CC: Interleukin-1beta-induced cyclooxygenase-2 expression is mediated through activation of p42/44 and p38 MAPKS, and NF-kappaB pathways in canine tracheal smooth muscle cells. Cell Signal. 2002, 14: 899-911.View ArticlePubMedGoogle Scholar
- Deng WG, Wu KK: Regulation of inducible nitric oxide synthase expression by p300 and p50 acetylation. J Immunol. 2003, 171: 6581-6588.View ArticlePubMedGoogle Scholar
- DiDonato J, Mercurio F, Rosette C, Wu-Li J, Suyang H, Ghosh S, Karin M: Mapping of the inducible IkappaB phosphorylation sites that signal its ubiquitination and degradation. Mol Cell Biol. 1996, 16: 1295-1304.PubMed CentralView ArticlePubMedGoogle Scholar
- Liu S, Misquitta YR, Olland A, Johnson MA, Kelleher KS, Kriz R, Lin LL, Stahl M, Mosyak L: Crystal structure of a human IkappaB kinase beta asymmetric dimer. J Biol Chem. 2013, 288: 22758-22767.PubMed CentralView ArticlePubMedGoogle Scholar
- Xu G, Lo YC, Li Q, Napolitano G, Wu X, Jiang X, Dreano M, Karin M, Wu H: Crystal structure of inhibitor of kappaB kinase beta. Nature. 2011, 472: 325-330.PubMed CentralView ArticlePubMedGoogle Scholar
- Li Q, Van Antwerp D, Mercurio F, Lee KF, Verma IM: Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. Science. 1999, 284: 321-325.View ArticlePubMedGoogle Scholar
- Li ZW, Chu W, Hu Y, Delhase M, Deerinck T, Ellisman M, Johnson R, Karin M: The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. J Exp Med. 1999, 189: 1839-1845.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.